I believe GC would want to keep most of the cash received from a lympro/diagnostics sale to fund ambs' main business, just my opinion.

I'm curious what becomes of the spun-off diagnostics company. Will it be left with a small amount of cash and some small portion of future lympro revenues? Will they be partially owned by another company? If they have no revenue for now and minimal cash -- just enough to operate until lympro revenues start paying the bills - then will the dx company qualify to remain on nasdaq? I'd say Gerald would want to keep the dx company's sharecount low if listing it on a national exchange is a priority. So maybe 1 for 10 stock distribution or greater since the fewer outstanding shares the better for the new dx company, imo.